Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cognitive Benefits of Treating Apnea in Dementia
Brief Summary: The purpose of this study is to determine whether treating sleep apnea with continuous positive airway pressure would result in improvements in cognition in patients with Alzheimer's disease.


Options:
A: Inclusion Criteria:

* diagnosis of OSA;
* 18-75 years;
* CPAP recommendation;
* Informed consent.

Exclusion Criteria:

* Disabling hypersomnia;
* Pregnancy;
* Psychiatric disorders;
* Previous treatment with CPAP;
* Clinical instability in the previous month;
* Inability to use information technologies (computers and web).
B: Inclusion Criteria:

* Clinical diagnosis of obstructive sleep apnea
* No previous use of CPAP
* Must be a Veteran with residence within San Diego County

Exclusion Criteria:

* Home oxygen therapy
* Fatal comorbidities (i.e., life expectancy less than 6 mos)
* Contraindications for CPAP use
C: Inclusion Criteria:

* Patients aged \> 18 years of age who are referred to the University of Chicago sleep laboratory for split-night polysomnography by a non-sleep physician and who have a consultation appointment with a sleep physician following the appointment
* Have not had prior contact with a sleep physician or prior exposure to CPAP therapy.

Exclusion Criteria: Subjects will be excluded for any of the following characteristics: -Non-English speaking

* Illiterate
* Sleep study is negative for sleep apnea (apnea-hypopnea index \< 5 events/hr)
* Subject does not undergo CPAP titration during the in-laboratory polysomnogram
* Subject does not have a working telephone number
* Poor eyesight or hearing
* Dementia
D: Inclusion Criteria:

* Mild probable Alzheimer's disease (diagnosed according to the National Institute of Neurological and Communicative Disorders \& Stroke-Alzheimer's Disease and Related Disorders Association \[NINCDS-ADRDA\] criteria).
* Mini Mental Status Exam score between 20 and 27
* Respiratory disturbance index \>15 (i.e., 15 apneas plus hypopneas per hour of sleep) - Between the ages of 50-85 years
* Stable health
* reliable caregiver
* English speaking
* Patients will be allowed to continue acetylcholinesterase inhibitors, psychotropic medications, memory enhancers, health food supplements, etc. as long as they have been stable on the same dose for at least two months prior to participation and agree to continue on this dose for the duration of the study.

Exclusion Criteria:

* Currently receiving treatment for sleep apnea.
* Apneas primarily central in origin; narcolepsy or other sleep disorders
* Medication known to influence sleep (i.e. sedative hypnotics, narcotics) will be excluded if the dose can not remain stable and unchanged for the duration of the study.
* Bronchospastic and symptomatic chronic obstructive pulmonary disease as indicated by regular use of bronchodilators, steroids, history of carbon dioxide retention, waking hypoxemia (PaO2 \<60 mmHg or SpO2 \<92 % by pulse oximetry), or use of supplemental oxygen.
* Symptomatic coronary or cerebral vascular disease (history of myocardial infarction, angina, stroke, or transient ischemic attacks), history of life-threatening arrhythmias, cardiomyopathy, history of psychosis, or current alcohol or drug abuse
* Current diagnosis of active uncontrolled seizure disorder
* Any other advanced, severe and unstable disease of any type that may put the subject at special risk or interfere with primary and secondary variable evaluations
* Change in any medication within one month of participation.

Answer: D